BioForce Announces New Sale to Harvard Medical School

Nov 09, 2006, 00:00 ET from BioForce Nanosciences, Inc.

    AMES, Iowa, Nov. 9 /PRNewswire-FirstCall/ -- BioForce Nanosciences,
 Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
 (OTC Bulletin Board:   BFNH.OB), announced today the completion of a Nano
 eNabler(TM) system sale to the Technology & Engineering Center at Harvard
 Medical School. Funding for the purchase was provided by an award from the
 National Human Genome Research Institute (NHGRI).
     "The completion of this sale marks an important event for BioForce as
 the company develops this new and exciting technology," notes Kerry Frey,
 chief operating officer of BioForce Nanosciences. "We are working to
 promote the unique opportunities that the Nano eNabler technology provides
 to assist researchers working with smaller platforms."
     Dale Larson, Director of the Technology and Engineering Center is
 leading the use of the Nano eNabler system. His group is utilizing the
 system to print very small femtoliter volumes of biomolecules onto
 specially developed nanohole array sensors with sub-micron dimensions. This
 technology is being developed for use in drug discovery and development,
 biomarker screening, diagnostic assays, and homeland security applications.
 The nanohole array sensing technology is a label-free detection system that
 is very sensitive and highly multiplexed. The Nano eNabler system enables
 the printing of many different capture agents on their chip, allowing
 researchers to simultaneously study many different binding interactions
 from one sample on one chip.
     Michael Lynch, BioForce product manager for the Nano eNabler system
 notes, "I am very pleased to be working with this key group of Harvard
 Medical School researchers. BioForce is focused on marketing this unique
 printing technology to researchers working in a variety of areas where
 these smaller micron and sub-micron dimensions are standard. As biosensors
 and nanosensors move from academic R&D into commercial product development,
 our printing technology will be called upon to address the needs of the
 production environment."
     About BioForce Nanosciences, Inc.
     BioForce Nanosciences is a nanotechnology tools and applications
 company, providing innovative and practical products that support the
 growth of the nanotechnology industry. BioForce has spent more than a
 decade on invention, research, and development of patented and
 patent-pending nanotechnology products. The core technology is the Nano
 eNabler(TM) bench-top molecular printer, a portal to new opportunities in
 nanotechnology. The Nano eNabler printing system opens the door to new and
 important applications in the biomedical and life sciences markets that
 lead to improved quality of life. BioForce continues to target inventions
 that further expand the reach of its proprietary technology and expand its
 robust patent, trademark, and IP portfolio.
     BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) Company,
 brings inventions to the marketplace that complement existing innovations,
 licensing and acquisitions. BioForce is a wholly owned subsidiary of
 BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board:   BFNH.OB). For
 more information, visit
     This news release contains forward-looking information that may be
 affected by certain risks and uncertainties, including those risks and
 uncertainties described in the Company's most recent filings with the
 Securities and Exchange Commission. The Company's actual results could
 differ materially from such forward-looking statements. We assume no duty
 to update these statements at any future date.

SOURCE BioForce Nanosciences, Inc.